Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation |
---|
Name (Synonyms) | Correlation | |
---|---|---|
D013577 | Syndrome NIH | 0.10 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.07 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a new coronavirus discovered in December 2019 in Wuhan, China and currently responsible of a worldwide outbreak and the death of more than 55,000 patients in France. The more severe form of COVID-19 disease induces a pneumonia with profound hypoxemia which may require invasive mechanical ventilation. It is estimated that 5% of COVID-19 patients are admitted to the Intensive Care Unit (ICU) for management. Hospital mortality in patients who develop severe acute respiratory distress syndrome (ARDS) ranges between 40% and 60%. The investigators purpose to investigate the pathological findings of COVID-19 patients who died from ARDS in the ICU by doing post-mortem lung biopsies
Description: Detailed description and analysis of the primary lesions of the lungs in patients who died in the ICU from Covid-19.
Measure: Analysis of the pathological findings of a large cohort of patients who died from COVID-19 in the ICU Time: Two post-mortem lung biopsies performed immediately after death.Description: Comparison of pathological findings according to the time between ICU admission and death.
Measure: Comparison between early (<1 week after ICU admission) and late (≥1 week) deaths Time: Two post-mortem lung biopsies performed immediately after death.Description: Comparison of pathological findings according to the length of acute respiratory syndrome.
Measure: Analysis of the influence of ARDS severity and length on pathological findings Time: Two post-mortem lung biopsies performed immediately after death.Description: Comparison of pathological findings according to the duration of acute respiratory syndrome.
Measure: Analysis of the influence of ARDS severity and length on pathological findings Time: Two post-mortem lung biopsies performed immediately after death.Description: Comparison of pathological findings between patients who received steroids and those who did not.
Measure: Analysis of the influence of pharmacological treatments (steroids) on pathological findings Time: Two post-mortem lung biopsies performed immediately after death.Description: Comparison between radiological description of the CT of the lungs and the radiological findings.
Measure: Analysis of the correlation between radiological findings and pathological findings Time: Two post-mortem lung biopsies performed immediately after death.Description: Analysis of the pathological findings according to the primary cause of death (hypoxia, shock, hypoxia and shock, cardiac arrest, other).
Measure: Association between the primary cause of death and pathological findings Time: Two post-mortem lung biopsies performed immediately after death.Description: Analysis of the correlation between the ventilator settings (tidal volume, PEEP, driving pressure, plateau pressure, static compliance, volume or pressure mode) and pathological findings.
Measure: Analysis of the correlation between the ventilator settings and pathological findings Time: Two post-mortem lung biopsies performed immediately after death.Description: Description of the co-infection (bacterial or fungal infections) documented by pathological findings
Measure: Co-infections Time: Two post-mortem lung biopsies performed immediately after death.Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports